Get the Stockscreener App
43.45
0.39%
0.17
After Hours:
43.45
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $87,160 in stock - Investing.com India
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - Marketscreener.com
Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan
H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK
Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView
Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma
UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times
Breakthrough: Cytokinetics HCM Drug Delivers Powerful 72-Week Heart Improvement Data - StockTitan
Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com Canada
Cytokinetics EVP Andrew Callos sells $4,500 in stock - Investing.com India
Cytokinetics’ EVP sells $4,500 in stock - Investing.com
Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa
Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks
Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com
Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks
Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise
Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com
Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com
Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India
Cytokinetics Executives Engage in Stock Transactions - TradingView
Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK
Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK
What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World
Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks
Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks
Cytokinetics Executives Cash In: Massive Stock Sales Unveiled! - TipRanks
Insider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus.com
Cytokinetics EVP Callos sells $47,768 in stock - Investing.com
Cytokinetics CEO Robert Blum sells $1.08 million in stock - Investing.com
Cytokinetics EVP Callos sells $47,768 in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics EVP sells $85,000 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $85,000 in stock - Investing.com India
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus - MSN
Cytokinetics to Participate in March Investor Conferences - The Manila Times
Where Can You Hear Cytokinetics' Latest Strategy? Three Upcoming Investor Conferences Revealed - StockTitan
Cytokinetics’ (CYTK) Buy Rating Reiterated at HC Wainwright - Defense World
New York State Common Retirement Fund Boosts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):